Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo (Nasdaq: NUVO) -- Ignore unavailable to you. Want to Upgrade?

To: 44magnumpower who wrote (196)	12/8/2000 4:59:48 PM
From: AustinPowersIII	Read Replies (2) \| Respond to of 286

HYSQ rockets up 28% Amgen's first CEO, George Rathmann, already had a very successful career and was at Abbot Laboratories (ABT) where he was head of diagnostic research. Rathmann led Amgen to its success from 1980 to 1988. He left Amgen to help start up another biotech success, ICOS Corporation. This year, he became CEO of Hyseq, a young company that aims to begin testing its first two drugs on humans in 2001. Maybe you want to consider Hyseq!"